| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public.
| Patented Medicine Prices Review Board Canada | news releases
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Pharma.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the report Drug Shortages in Canada and their Impact on Public Drug Plans, 2017/18 to 2019/20, which provides insight into the impact of drug shortages in Canada, focusing on the effects on Canadian public drug plans and their beneficiaries.
| Patented Medicine Prices Review Board Canada | news releases
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel has issued an Order relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc.
| Patented Medicine Prices Review Board Canada | news releases
An average of nine new medicines per quarter have been approved in Canada through the pandemic, with many more products moving through clinical trials.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board will hold a public rehearing in the matter of the price of the patented medicine Soliris, and Alexion Pharmaceuticals Inc., the pharmaceutical company that holds the patent for Soliris and sells the medicine in Canada.
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Jean-Yves Duclos, Federal Minister of Health, yesterday tabled the 2020 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the House of Commons and the Senate.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) released today the third and final part in the Alignment Among Public Formularies in Canada series, which explores the current gaps and overlaps in Canadian public drug plan formularies
| Patented Medicine Prices Review Board Canada | news releases
Patented Medicine Prices Review Board seeks applicants for Chairperson position
| Patented Medicine Prices Review Board Canada | news releases
High-cost drugs accounted for over one third of total drug costs in 2019-20 but were only used by 2% of beneficiaries.
